猫疫苗市场机会、成长驱动因素、产业趋势分析与预测 2025 - 2034 年

2024年全球猫疫苗市场价值为11亿美元，预计2025年至2034年复合年增长率为9.2%。疫苗接种对于保护猫免受传染病至关重要，包括猫白血病、呼吸道疾病和狂犬病，这些疾病在家猫和流浪猫中都很常见。随着越来越多的人了解宠物预防性保健的重要性，对猫疫苗的需求持续上升。

此外，人们越来越关注可以从动物传播给人类的人畜共患疾病，这增加了对疫苗接种的重视，特别是预防狂犬病等疾病。这种意识的增强导致疫苗的使用量增加，越来越多的宠物主人投资于猫咪健康的预防措施。此外，宠物保险的扩大使用以及宠物护理产品和服务的激增也促进了市场的成长。

猫疫苗旨在保护伴侣动物，尤其是猫，免受一系列传染病的侵害。这些疫苗透过刺激免疫系统发挥作用，从而防止疾病传播并促进室内和室外猫的整体健康。

市场依疫苗类型分为改良/减毒活疫苗、灭活疫苗和其他疫苗类型。改良/减毒活疫苗所占份额最大，到2024年将占市场的50.5%。这些疫苗可以针对猫白血病、全白血球减少症和呼吸道疾病等疾病提供持久的保护，特别是在动物收容所等高风险环境中。

猫疫苗市场也依疾病类型分为猫白血病、全白血球减少症、呼吸道疾病、狂犬病等类别。猫呼吸道疾病，包括猫疱疹病毒和杯状病毒，占最大部分，因为它们具有高度传染性，并且对猫具有重大健康风险，特别是在多猫环境中。

疫苗经由注射或鼻内途径施用。注射疫苗因其经过验证的有效性、易于使用和快速的免疫反应而在市场上占据主导地位。这些疫苗通常以组合配方形式提供，单剂量即可提供针对多种疾病的保护，使它们对宠物主人来说既方便又有吸引力。

联合疫苗领域引领市场，一次性提供多种疾病的保护。这些疫苗减少了去看兽医和注射的次数，使猫更负担得起并减轻压力。

市场也根据免疫期限进行细分，疫苗提供 1 年、3 年或其他期限。一年期免疫疫苗最受欢迎，以其长期的安全记录和功效而闻名，巩固了其在市场上的主导地位。

在北美，由于拥有大量宠物的人口和强大的兽医基础设施，美国占有重要的市场份额，这增加了获得疫苗和兽医护理的机会，进一步促进了市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

• 产业生态系统分析
• 产业影响力
  • 成长动力
    • 增加宠物拥有量和宠物健康支出
    • 预防性宠物保健意识不断增强
    • 疫苗技术的进步
  • 产业陷阱与挑战
    • 疫苗研发成本高
    • 严格的监管要求
• 成长潜力分析
• 监管环境
• 管道分析
• 未来市场趋势
• 波特的分析
• PESTEL分析

第 4 章：竞争格局

• 介绍
• 公司矩阵分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 战略仪表板

第 5 章：市场估计与预测：按疫苗类型，2021 - 2034 年

• 主要趋势
• 修改/减弱的现场
• 灭活
• 其他疫苗类型

第 6 章：市场估计与预测：按疾病类型，2021 - 2034 年

• 主要趋势
• 猫呼吸道疾病
• 猫白血病
• 猫泛白血球减少症（猫瘟）
• 猫咪狂犬病
• 其他疾病类型

第 7 章：市场估计与预测：按管理途径，2021 - 2034 年

• 主要趋势
• 注射剂
• 鼻内

第 8 章：市场估计与预测：按组成部分，2021 - 2034 年

• 主要趋势
• 联合疫苗
• 单一疫苗

第 9 章：市场估计与预测：按豁免期限划分，2021 - 2034 年

• 主要趋势
• 1年
• 3年
• 其他免疫期限

第 10 章：市场估计与预测：按地区划分，2021 - 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 义大利
  • 西班牙
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 沙乌地阿拉伯
  • 阿联酋

第 11 章：公司简介

• Bioveta
• Boehringer Ingelheim
• Durvet
• Elanco
• Indian Immunologicals
• INTAS Animal Health
• Merck
• Spectra
• Virbac
• Zoetis

The Global Cat Vaccines Market, valued at USD 1.1 billion in 2024, is anticipated to grow at a CAGR of 9.2% from 2025 to 2034. The primary drivers of this market expansion include the rising awareness of animal health and an increasing number of pet owners worldwide. Vaccination is critical in safeguarding cats from infectious diseases, including feline leukemia, respiratory conditions, and rabies, which are common among both domestic and stray cats. As more people understand the importance of preventative healthcare for their pets, the demand for cat vaccines continues to rise.

Additionally, the growing concern over zoonotic diseases, which can be transmitted from animals to humans, has increased the emphasis on vaccinations, particularly to prevent diseases like rabies. This growing awareness has led to an increased uptake of vaccines, with more pet owners investing in preventive measures for their cats' health. Furthermore, the expanding use of pet insurance and the surge in pet care products and services also contribute to the market growth.

Cat vaccines are designed to protect companion animals, especially cats, from a range of infectious diseases. These vaccines work by stimulating the immune system, thereby preventing the spread of illnesses and promoting the overall health of both indoor and outdoor cats.

The market is segmented based on vaccine type into modified/attenuated live, inactivated, and other vaccine types. The modified/attenuated live vaccines hold the largest share, accounting for 50.5% of the market in 2024. Their effectiveness, ability to trigger strong immune responses, and cost-effectiveness make them highly favored by veterinarians and pet owners. These vaccines provide long-lasting protection against diseases like feline leukemia, panleukopenia, and respiratory illnesses, particularly in high-risk environments such as animal shelters.

The cat vaccines market is also divided by disease type into categories like feline leukemia, panleukopenia, respiratory diseases, rabies, and others. Feline respiratory diseases, including Feline Herpesvirus and Calicivirus, represent the largest segment, due to their high contagiousness and significant health risks to cats, particularly in multi-cat environments.

The vaccines are administered either through injectables or intranasal routes. Injectable vaccines dominate the market because of their proven effectiveness, ease of use, and quick immune response. These vaccines, often available in combination formulations, provide protection against multiple diseases in a single dose, making them convenient and appealing to pet owners.

The combined vaccines segment leads the market, offering protection against several diseases in one shot. These vaccines reduce the number of vet visits and injections, making them more affordable and less stressful for cats.

The market is also segmented by the duration of immunity, with vaccines offering 1-year, 3-year, or other durations. The 1-year immunity vaccines are the most popular, known for their long-standing safety record and efficacy, which solidifies their dominant position in the market.

In North America, the U.S. holds a significant market share, driven by its large pet-owning population and strong veterinary infrastructure, which enhances access to vaccines and veterinary care, further promoting market growth.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Increasing pet ownership and spending on pet health
    • 3.2.1.2 Growing awareness of preventive pet healthcare
    • 3.2.1.3 Advancements in vaccine technology
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 High development cost of vaccines
    • 3.2.2.2 Stringent regulatory requirement
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Pipeline analysis
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Competitive analysis of major market players
• 4.4 Competitive positioning matrix
• 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Vaccine Type, 2021 - 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Modified/attenuated live
• 5.3 Inactivated
• 5.4 Other vaccine types

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Feline respiratory diseases
• 6.3 Feline leukemia
• 6.4 Feline panleukopenia (feline distemper)
• 6.5 Feline rabies
• 6.6 Other disease types

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Injectables
• 7.3 Intranasal

Chapter 8 Market Estimates and Forecast, By Component, 2021 - 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Combined vaccine
• 8.3 Mono vaccine

Chapter 9 Market Estimates and Forecast, By Duration of Immunity, 2021 - 2034 ($ Mn)

• 9.1 Key trends
• 9.2 1 year
• 9.3 3 years
• 9.4 Other durations of immunity

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2034 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Italy
  • 10.3.5 Spain
  • 10.3.6 Netherlands
• 10.4 Asia Pacific
  • 10.4.1 China
  • 10.4.2 Japan
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Argentina
• 10.6 Middle East and Africa
  • 10.6.1 South Africa
  • 10.6.2 Saudi Arabia
  • 10.6.3 UAE

Chapter 11 Company Profiles

• 11.1 Bioveta
• 11.2 Boehringer Ingelheim
• 11.3 Durvet
• 11.4 Elanco
• 11.5 Indian Immunologicals
• 11.6 INTAS Animal Health
• 11.7 Merck
• 11.8 Spectra
• 11.9 Virbac
• 11.10 Zoetis